Cargando…

Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States

INTRODUCTION: Vaginal rings are a promising approach to provide a woman‐centred, long‐acting HIV prevention strategy. Prior trials of a 25 mg dapivirine (DPV) ring have shown a favourable safety profile and approximately 30% risk reduction of HIV‐1 infection. Extended duration rings replaced every t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Albert Y, Dominguez Islas, Clara, Gundacker, Holly, Neradilek, Blazej, Hoesley, Craig, van der Straten, Ariane, Hendrix, Craig W, Beamer, May, Jacobson, Cindy E, McClure, Tara, Harrell, Tanya, Bunge, Katherine, Devlin, Brid, Nuttall, Jeremy, Spence, Patrick, Steytler, John, Piper, Jeanna M, Marzinke, Mark A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196716/ https://www.ncbi.nlm.nih.gov/pubmed/34118115 http://dx.doi.org/10.1002/jia2.25747

Ejemplares similares

Increased Dapivirine Tissue Accumulation through Vaginal Film Codelivery of Dapivirine and Tenofovir
por: Akil, Ayman, et al.
Publicado: (2014)

Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women
por: Shapley-Quinn, Mary Kate, et al.
Publicado: (2022)

Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV‐1 acquisition: a secondary analysis from a randomized, placebo‐controlled trial
por: Brown, Elizabeth R, et al.
Publicado: (2020)

Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial
por: Dezzutti, Charlene S., et al.
Publicado: (2016)

Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial
por: Roberts, Sarah T., et al.
Publicado: (2022)

Refining the in vitro release test method for a dapivirine-releasing vaginal ring to match in vivo performance
por: Murphy, Diarmaid J., et al.
Publicado: (2021)

Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study
por: van der Straten, Ariane, et al.
Publicado: (2016)

Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel
por: Dallal Bashi, Yahya H., et al.
Publicado: (2021)

Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring
por: Stoner, Marie C. D., et al.
Publicado: (2022)

Design of Poly(lactic-co-glycolic Acid) (PLGA) Nanoparticles for Vaginal Co-Delivery of Griffithsin and Dapivirine and Their Synergistic Effect for HIV Prophylaxis
por: Yang, Haitao, et al.
Publicado: (2019)

In vitro drug release, mechanical performance and stability testing of a custom silicone elastomer vaginal ring releasing dapivirine and levonorgestrel
por: Murphy, Diarmaid J., et al.
Publicado: (2022)

Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions
por: Zheng, Ruohui, et al.
Publicado: (2022)

Assessing pregnancy and neonatal outcomes in Malawi, South Africa, Uganda, and Zimbabwe: Results from a systematic chart review
por: Balkus, Jennifer E., et al.
Publicado: (2021)

Investigating the Contribution of Drug-Metabolizing Enzymes in Drug-Drug Interactions of Dapivirine and Miconazole
por: Valicherla, Guru Raghavendra, et al.
Publicado: (2021)

Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls
por: Farr Zuend, Christina, et al.
Publicado: (2021)

Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
por: Mayo, Ashley J., et al.
Publicado: (2021)

Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention
por: Palanee-Phillips, Thesla, et al.
Publicado: (2015)

Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa
por: Nel, Annalene, et al.
Publicado: (2016)

Adolescent Girls and Young Women’s Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis
por: Young, Alinda M., et al.
Publicado: (2023)

Multiple dosage forms of the NNRTI microbicide dapivirine: product development and evaluation
por: Romano, Joseph
Publicado: (2006)

Antitumor Activity and Mechanism of a Reverse Transcriptase Inhibitor, Dapivirine, in Glioblastoma
por: Liu, Weiwen, et al.
Publicado: (2018)

Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study
por: Garcia, Morgan, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic model of vaginally administered dapivirine ring and film formulations
por: Kay, Katherine, et al.
Publicado: (2018)

Assessment of risk compensation following use of the dapivirine vaginal ring in southwestern Uganda
por: Kusemererwa, Sylvia, et al.
Publicado: (2022)

Inhibition of HIV Virus by Neutralizing Vhh Attached to Dual Functional Liposomes Encapsulating Dapivirine
por: Wang, Scarlet Xiaoyan, et al.
Publicado: (2016)

Dapivirine Bioadhesive Vaginal Tablets Based on Natural Polymers for the Prevention of Sexual Transmission of HIV
por: Cazorla-Luna, Raúl, et al.
Publicado: (2019)

Rational Design of a Multipurpose Bioadhesive Vaginal Film for Co-Delivery of Dapivirine and Levonorgestrel
por: Li, Jing, et al.
Publicado: (2019)

A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)
por: Mcgowan, Ian, et al.
Publicado: (2013)

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost‐effectiveness
por: Glaubius, Robert, et al.
Publicado: (2019)

HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial
por: Parikh, Urvi M., et al.
Publicado: (2021)

A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy
por: Beigi, Richard H, et al.
Publicado: (2016)

Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention
por: Reidy, Meghan, et al.
Publicado: (2019)

A randomized trial of safety, acceptability and adherence of three rectal microbicide placebo formulations among young sexual and gender minorities who engage in receptive anal intercourse (MTN-035)
por: Bauermeister, Jose A., et al.
Publicado: (2023)

Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study)
por: Ngure, Kenneth, et al.
Publicado: (2023)

Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study
por: van der Straten, Ariane, et al.
Publicado: (2020)

Sexual Attitudes, Beliefs, Practices, and HIV Risk During Pregnancy and Post-delivery: A Qualitative Study in Malawi, South Africa, Uganda, and Zimbabwe
por: Ryan, Julia H., et al.
Publicado: (2021)

Beyond the first 25 years: The International AIDS Society and its role in the global response to AIDS
por: Cahn, Pedro, et al.
Publicado: (2006)

Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
por: Scott, Rachel K., et al.
Publicado: (2023)

Participant experiences with a multipurpose vaginal ring for HIV and pregnancy prevention during a phase 1 clinical trial: learning from users to improve acceptability
por: Shapley-Quinn, Mary Kate, et al.
Publicado: (2023)

Post-use assay of vaginal rings (VRs) as a potential measure of clinical trial adherence
por: Spence, Patrick, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_72cg1intggshq4d9hn9107jg8a